AUPH

Voclosporin Ophthalmic Solution

Dry Eye Syndrome

Discontinued

Exp Date

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: Voclosporin for dry eye syndrome 

  • ClinicalTrial.gov (NCT04147650): Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome (AUDREY)


WHAT IS THE CATALYST EVENT?

  • TBD


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • TBD


PAST DATA/EVENTS 


PRESS RELEASES

POSTERS


PRESENTATIONS

PUBLICATIONS


MECHANISM OF ACTION / RATIONALE

COMPETITORS


Calcineurin inhibitor:

MARKET

Updated by MV

AUPH,Voclosporin, AUDREY, Dry Eye Syndrome, ophthalmology

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

AUPH - Aurinia Announces Outco...

Summary: The trial did not achieve statistical significance on the primary endpoint of ≥ 10mm improvement in Schirmer Tear Test (STT) at 4 weeks Company to suspend development program for voclosporin ...

AUPH Ph3 data in lupus nephrit...

AUPH reported encouraging phase 3 results in December (12/4/19) in lupus nephritis, an inflammation of the kidney caused by SLE. Its calcineurin inhibitor drug candidate voclosporin met its primary en...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon